Janssen's hepatitis C drug gets FDA panel endorsement

10/25/2013 | Medscape (free registration) · PharmaTimes (U.K.)

An FDA panel endorsed the approval of Janssen's simeprevir to be used in combination with peginterferon alfa and ribavirin to treat chronic hepatitis C in treatment-naive adults with compensated liver disease. The therapy is also intended for patients who did not respond to previous interferon treatment.

View Full Article in:

Medscape (free registration) · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY